Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 1/20 | 0.58 |
| ▸ | TPX2 | Q9ULW0 | 1/20 | 0.58 |
| ▸ | KIF11 | P52732 | 2/20 | 0.51 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.50 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.45 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.45 |
| ▸ | ABL1 | P00519 | 2/20 | 0.43 |
| ▸ | BCR | P11274 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | CASP3 | P42574 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.42 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.42 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.42 |
| ▸ | PPARD | Q03181 | 2/20 | 0.42 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.41 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL309510 | 0.82 | NPC1 (0.66) | PTGS2ABL1BCRNPC1TP53 | |
| SCHEMBL7673984 | 0.81 | PTGS2 (0.68) | KIF11PTGS2ABL1BCRTP53 | |
| SCHEMBL12952736 | 0.81 | AURKA (0.71) | AURKATPX2KIF11AKR1C2AKR1C1 | |
| SCHEMBL1690017 | 0.81 | AURKA (0.71) | AURKATPX2KIF11AKR1C2AKR1C1 | |
| SCHEMBL21944789 | 0.78 | AURKA (0.67) | AURKATPX2KIF11AKR1C2AKR1C1 | |
| SCHEMBL514383 | 0.76 | PTGS2 (0.65) | KIF11PTGS2ABL1BCRTP53 | |
| SCHEMBL309425 | 0.75 | EGFR (0.49) | PTGS2 | |
| SCHEMBL309551 | 0.72 | LOX (0.49) | PTGS2PTGS1 | |
| SCHEMBL508237 | 0.72 | AURKA (0.57) | AURKATPX2KIF11AKR1C2AKR1C1 | |
| SCHEMBL21944912 | 0.72 | KIF11 (0.51) | KIF11PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8093253-B2 | Leukotriene B4 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2012-01-10 | — | — | US | disclosed |
| US-8093253-B2 | Leukotriene B4 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2012-01-10 | — | — | US | disclosed |
| US-8093253-B2 | Leukotriene B4 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2012-01-10 | — | — | US | disclosed |
| EP-2250150-A1 | LEUKOTRIENE B4 INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2010-11-17 | — | — | EP | disclosed |
| WO-2009109483-A1 | LEUKOTRIENE B4 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-09-11 | — | — | WO | disclosed |
| WO-2009109483-A1 | LEUKOTRIENE B4 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-09-11 | — | — | WO | disclosed |
| US-20090227603-A1 | LEUKOTRIENE B4 INHIBITORS | DOMINIQUE ROMYR | 2009-09-10 | — | — | US | disclosed |
| US-20090227603-A1 | LEUKOTRIENE B4 INHIBITORS | DOMINIQUE ROMYR | 2009-09-10 | — | — | US | disclosed |
| US-20090227603-A1 | LEUKOTRIENE B4 INHIBITORS | DOMINIQUE ROMYR | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227603-A1 | LEUKOTRIENE B4 INHIBITORS | LTB4R2, LTB4R, LTC4S | AURKA 4571/4885TPX2 1202/4885KIF11 4626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.